Uncategorized

TRWR submitted diabetes bioelectronic medicine market approval application to Taiwan FDA in April 2022. TRWR’s diabetes bioelectronic medicine is the first application of transcutaneous electrical nerve stimulation as diabetes’s adjunctive treatment. Without predicates, the market approval application review process of our diabetes bioelectronic medicine is...

The Healthcare+ Expo Taiwan this year was held from Dec 1st to 4th 2022 in Hall 1, Taipei Nangang Exhibition Center. The expo brought together influential healthcare groups, ICT tech giants, and leading biomedical companies, gathering all players in the entire health industry ecosystem. TRWR...

Our randomized, double-blind trial is underway at National Taiwan University Hospital, National Cheng Kung University Hospital, and two other medical facilities. Under the investigative leadership of 20 medical professionals, the study is expected to be completed in 2018 and potentially become the world’s first non-invasive electronic medical device used to alleviate symptoms associated with type 2 diabetes.